BCL2L1 and gastric cancer: In our study, we found that nasopharyngeal, breast and gastric cancer cell lines resistant to gemcitabine had higher Bcl-2 expression, and treatment with gemcitabine resulted in an up-regulation of anti-apoptotic Bcl-2 or Bcl-xl.